Regarding immune checkpoints, PDCD1, TMIGD2, TNFSF14, TNFRSF18, CD44, LGALS9, and LAG3 expression were higher in the high-risk group than in the low-risk group.Seaman et al. demonstrated that the cell surface protein CD276/B7-H3 is overexpressed in several cancers and tumor-infiltrating vessels; CD276 antibody-medication conjugates (ADCs) equipped with conventional monomethyl auristatin E warheads could kill CD276-positive cancer cells but have little effect on tumor vasculature. This evidence concerns the gene TNFRSF18 and neoplasm.